Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871
Status:
Completed
Trial end date:
2017-08-18
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the effects of AZD8871 in patients with COPD. Adult male or
female patients with moderate to severe COPD, who agree to be in this study, will receive 3
treatments, i.e. 2 different doses of AZD8871 and placebo (dummy medication containing no
drug) at once a day for 2 weeks, in a random order. To make the comparison between AZD8871
and placebo as fair as possible, this study is "double blinded." This means that neither
patient nor the study doctor will know in which order the 3 treatments will be given. This
study will include patients who are between 40 and 80 years of age. In total there will be 42
patients participating in this study at two study centers in the United Kingdom and Germany.
The study will have a total of 12 visits for each patient spanning for a period of 4 to 6
months. The study is anticipated to run for approximately 8 months and should not exceed 10
months.